Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024

Corvus Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.86

Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.
Cash, equivalents and marketable securities $41.7M at Sep 30, 2024; projected year-end cash $38-39M.
October 2024 early warrant exercise raised $5.9M; approx. 15.4M warrants outstanding expiring June 2025.
Soquelitinib Phase 1 atopic dermatitis trial second cohort (200mg QD) enrolling; interim data expected Dec 2024.
Soquelitinib Phase 3 PTCL registrational trial enrolling at multiple sites; Orphan Drug and Fast Track granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.